Tenaya Therapeutics is a developer of novel therapies designed to offer treatment for heart disease.
Tenaya Therapeutics is a developer of novel therapies designed to offer treatment for heart disease. The company's therapies address heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle and that leverage cutting-edge research in cardiac development and regeneration, enabling physicians to regenerate heart tissue, and additional programs focused on cardiomyopathies.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 17, 2022 | Post-IPO Equity | $75M | — | — | — | Detail |
Jul 29, 2021 | IPO | $180M | — | — | — | Detail |
Mar 1, 2021 | Series C | $106M | 7 | RTW Investments | — | Detail |
Oct 3, 2019 | Series B | $92M | 4 | Casdin Capital | — | Detail |
Dec 6, 2016 | Series A | $50M | 1 | The Column Group | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
RTW Investments | Yes | Series C |
Casdin Capital | — | Series C |
Fidelity Management and Research Company | — | Series C |
GV | — | Series C |
RA Capital Management | — | Series C |
T. Rowe Price | — | Series C |
The Column Group | — | Series C |
Greenspring Associates | — | Series B |